Hepatera Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Moscow Russian Federation (2011)

Organization Overview

First Clinical Trial
2012
NCT02881008
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Hepatera Ltd.